AbbVie’s Allergan reaches $2B opioid lawsuit settlement – Bloomberg News

AbbVie’s Allergan reaches $2B opioid lawsuit settlement – Bloomberg News

July 27 (Reuters) – AbbVie Inc.’s (ABBV.N) unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter.

A screen displays the share price for drugmaker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid

The deal would settle more than 3,000 lawsuits filed by state and local governments, but complete terms of the settlement are still being chalked out, according to the report. Thousands of lawsuits have been filed against drugmakers, distributors and pharmacies over the U.S. opioid crisis.

Israel-based Teva Pharmaceutical Industries (TEVA.TA) on Tuesday announced a $4.35 billion proposed nationwide settlement of its U.S. opioid lawsuits.

AbbVie did not immediately respond to a Reuters request for a comment.

Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri

Our Standards: The Thomson Reuters Trust Principles.

/by
You might also like
OxycontinUS asks Supreme Court to delay Purdue Pharma bankruptcy settlement
AbbVieAbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
FDAReutersUS FDA approves first OTC opioid overdose reversal drug
CVS, Walmart, WalgreensCVS, Walmart, Walgreens agree to pay $13.8 bln to settle U.S. opioid claims
tug of war, money9 top biopharma CEO-to-employee pay gaps
AbbVieAbbVie, Eli Lilly exit UK drug pricing agreement
JanssenIbrutinib combos target hard-to-treat CML and MCL at ASH 2022
AbbVieAbbVie’s blood cancer combo therapy fails in late-stage study